United States: Federal Circuit Clarifies Calculation Of Patent Term Adjustment For Applications With Continued Examination Requests

Last Updated: January 25 2014
Article by Fabian M. Koenigbauer and Mark R. Shanks

In a recent ruling, the Federal Circuit clarified the scope of available Patent Term Adjustment (PTA) resulting from the U.S. Patent and Trademark Office's (PTO) failure to issue a patent within three years from the date the application was filed, for applications in which a request for continued examination (RCE) was made. Novartis AG v. Lee, 2013-1160, 2013-1179 (Fed. Cir. Jan. 15, 2014). Under the decision, PTA is not available for the period of prosecuting the RCE to allowance, but is available for the period from allowance to issuance.

Background on PTA and Recent Challenges to the PTO's Interpretation of B Delay

The term of a U.S. utility patent is 20 years measured from the filing date of the application. However, in practical terms, the patent application provides no benefit to the patentee until the day it issues as a patent from the PTO. Consequently, excessive delays at the PTO would significantly reduce the "effective" term of the patent. To avoid this result, Congress established a system of patent term adjustment that adds time to the end of a patent's life to offset certain kinds of delays encountered at the PTO.

Under this system, a patent is entitled to PTA based on delays attributable to the PTO. Specifically, the patent statute provides for PTA for three categories of patent office delays:

  1. "A delays" for failure of the PTO to act promptly, including its failure to issue a first Office Action within fourteen months from the filing date, or to respond to any applicant action within four months;
  2. "B delays" for failure of the PTO to issue a patent within three years of the filing date of the application (or entry of an international application into the National Stage); and
  3. "C delays" which accrue when an application is delayed due to a secrecy order, interference, derivation proceeding or appeal.

Notably, the statute provides certain exceptions to what would otherwise fall within B delay. For example, B delay does not include "any time consumed by continued examination of the application requested by the applicant." According to the PTO's rules, "time consumed by continued examination" is the period beginning when an RCE is filed and ending on the issue date of the patent.

Many patent owners have challenged the PTO's interpretation of what constitutes B delay in the situation where an RCE was filed more than three years after the application filing date. Exelixis, Inc. v. Kappos, 906 F. Supp. 2d 474 (E.D. Va. 2012) (Exelixis I) was the first case to address how to calculate B delay in such a situation. In Exelixis I, the court interpreted the statute's disallowance of RCE prosecution time to hinge upon the timing of when the RCE was filed. Specifically, the court held that the time spent prosecuting an RCE was only disallowed in calculating B delay when the RCE was filed within three years of the application filing date. If the RCE was filed after the three-year date, time spent prosecuting it was eligible for PTA on a day-for-day basis. Similarly, in Novartis A.G. v. Kappos, 904 F. Supp. 2d 58 (D. D.C. 2012), the District Court for the District of Columbia sided with the reasoning in Exelixis I and held that an RCE filed after the three-year date did not diminish B delay-related PTA.

However, in a subsequent case brought by Exelixis on the issue, (Exelixis, Inc. v. Kappos, 2013 WL 314754 (E.D. Va. Jan. 28, 2013) (Exelixis II)), the court took a contrary position and held that an RCE, no matter when it is filed, serves to toll B delay. Thus, under Exelixis II, time consumed by continued examination is always excludable from a PTA calculation. This decision created a split of authority within the Eastern District of Virginia on this issue. Since Exelixis I was decided, more than one hundred new PTA cases have been filed in the Eastern District of Virginia.

The Exelixis cases were consolidated on appeal, and the Novartis case was separately appealed. On November 5, 2013, the Federal Circuit heard oral arguments for all three cases. The Court subsequently issued a precedential opinion in Novartis and remanded the Exelixis cases in light of its Novartis decision.

The Federal Circuit Interprets B Delay to Exclude Time Spent Prosecuting RCE to Allowance Regardless of When RCE is Filed

The main issue in Novartis was the statutory interpretation of the B delay carve-out for "time consumed by continued examination." In addressing the issue, the Federal Circuit disposed of the Exelixis I interpretation of the statute, noting that such an interpretation "runs counter to the textual fact that there is no time-of-initiation restriction on the processes identified in the exclusions, including continued examination." Rather, the Court concluded that B delay "should be calculated by determining the length of time between application and patent issuance, then subtracting any continued examination time (and any other [exceptions]...) and determining the extent to which the result exceeds three years." Thus, "time spent in continued examination does not deplete the PTO's allotment of three years for application processing before a resulting patent has its term extended, no matter when continued examination begins."

As for the amount of time to be subtracted in determining B delay, the Federal Circuit further clarified that "time consumed by continued examination" does not include the time from allowance to issuance, as "such time is plainly attributable to the PTO." The Court reasoned that "examination" ends at allowance after prosecution on the merits has closed and no further examination on the merits occurs. Noting that the time from allowance to issuance undisputedly would count toward the PTO's three-year allotment in a case not involving a continued examination, the court found no basis for distinguishing a continued examination case. Thus, "'time consumed by continued examination,' 35 U.S.C. §154(b)(1)(B)(i), is the time up to allowance but not later, unless examination on the merits resumes."

Considerations for Patent Owners

First, since the period of time from allowance to issuance, if after three years from filing, is now eligible for PTA even when an RCE was filed, it may now be advantageous in some cases to delay paying the issue fee until close to the deadline in order to maximize the PTA.

Second, the Patent Office has not yet issued any internal guidance or revised its rules to account for the Novartis decision. Until the Office revises its procedures, it is unlikely that the PTA reported on the face of any patents that were prosecuted for more than three years and that included an RCE will be calculated correctly. However, since challenges to a PTA determination have to be filed within two months of the patent issuance (extendable by payment of fees for a total of seven months), correction of the mistake is only available for patents issued less than seven months ago. Accordingly, any patents issuing in the past seven months, as well as those that issue henceforth, should be reviewed for applicability of the change to the RCE exclusion mandated by the Novartis decision.

If you have any questions regarding PTA calculations, do not hesitate to contact our patent practitioners.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
Foley & Lardner
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
Foley & Lardner
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions